Canadian diagnostic company Metabolomic Technologies (MTI) said it will expand distribution of its PolypDx diagnostic test through a non-exclusive licensing and distribution agreement with Evolution Laboratories.
The value was not disclosed for the multi-year agreement, which covers MTI’s flagship product PolypDx. The test is designed to detect adenomatous polyps based on a unique “fingerprint” of metabolites from a urine test. PolypDx is non-invasive and does not require any dietary restrictions or fecal collections.
Distribution of PolypDx will be expanded into Arizona, California, Nevada, Texas, and Utah through the agreement, signed by MTI and Wyoming-based diagnostic testing company Evolution Laboratories in association with testing services provider Lab Express.
“This agreement expands our coverage of PolypDx in the western U.S. and ensures better access to all patients for a simple and accurate test with proven capacity to detect adenomatous colonic polyps and thereby prevent colon cancer,” MTI COO David Chang, MASc, Ph.D., said in a statement.
According to MTI, PolypDx has shown significantly higher sensitivity than current fecal-based screening tests to detect adenomatous polyps in a Canadian-based clinical trial of nearly 1,000 patients.
Last year, MTI said it signed a “multi-million dollar” exclusive licensing and distribution agreement with Atlantic Diagnostic Laboratories that facilitated the initial introduction of PolypDx across 12 eastern U.S. states.
Based in Edmonton, Alberta, Canada, MTI is a University of Alberta spin-off focused on developing metabolomics-based diagnostic systems created from proprietary biomarker technologies. Lab Express provides diagnostic testing services to healthcare companies throughout Arizona and Nevada.
